MX2011007936A - Metodos para regeneracion de tejido pancreatico. - Google Patents

Metodos para regeneracion de tejido pancreatico.

Info

Publication number
MX2011007936A
MX2011007936A MX2011007936A MX2011007936A MX2011007936A MX 2011007936 A MX2011007936 A MX 2011007936A MX 2011007936 A MX2011007936 A MX 2011007936A MX 2011007936 A MX2011007936 A MX 2011007936A MX 2011007936 A MX2011007936 A MX 2011007936A
Authority
MX
Mexico
Prior art keywords
methods
tissue regeneration
pancreatic tissue
pancreatic
conditions
Prior art date
Application number
MX2011007936A
Other languages
English (en)
Inventor
Linda Burkly
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MX2011007936A publication Critical patent/MX2011007936A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen métodos para expandir poblaciones de células pancreáticas o para inducir la generación de células progenitoras pancreáticas en un sujeto o en cultivo utilizando una cantidad terapéuticamente eficaz de un agonista de receptor de TWEAK. Estos métodos se pueden utilizar para tratar enfermedades o condiciones en donde es deseable el mejoramiento de células progenitoras pancreáticas para tratamiento de sustitución celular, que incluyen, por ejemplo, diabetes y condiciones que resultan en pérdida de la totalidad o parte del páncreas.
MX2011007936A 2009-01-30 2010-01-29 Metodos para regeneracion de tejido pancreatico. MX2011007936A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14870109P 2009-01-30 2009-01-30
PCT/US2010/022610 WO2010088534A1 (en) 2009-01-30 2010-01-29 Methods for pancreatic tissue regeneration

Publications (1)

Publication Number Publication Date
MX2011007936A true MX2011007936A (es) 2011-08-17

Family

ID=42396042

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007936A MX2011007936A (es) 2009-01-30 2010-01-29 Metodos para regeneracion de tejido pancreatico.

Country Status (10)

Country Link
US (2) US20120020913A1 (es)
EP (1) EP2391385A4 (es)
JP (1) JP2012516712A (es)
KR (1) KR20110117690A (es)
CN (1) CN102378634A (es)
AU (1) AU2010208123A1 (es)
BR (1) BRPI1007529A2 (es)
CA (1) CA2751261A1 (es)
MX (1) MX2011007936A (es)
WO (1) WO2010088534A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007163A (es) 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
NZ548701A (en) 2002-04-09 2008-03-28 Biogen Idec Inc Methods for treating tweak-related conditions
AU2006214179A1 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating neurological disorders
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US11534466B2 (en) * 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
CN111440761A (zh) * 2020-04-09 2020-07-24 上海赛尔维医疗科技有限公司 胰腺细胞的扩增和分化方法以及应用
JP2024516548A (ja) 2021-04-08 2024-04-16 ジョスリン ダイアビーティス センター インコーポレイテッド 腎機能低下の診断及び予測の方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946293B1 (en) * 1999-02-10 2005-09-20 Es Cell International Pte Ltd. Progenitor cells, methods and uses related thereto
NZ548701A (en) * 2002-04-09 2008-03-28 Biogen Idec Inc Methods for treating tweak-related conditions
US7628988B2 (en) * 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004074433A2 (en) * 2003-01-30 2004-09-02 Yale University Rag polypeptides, nucleic acids, and their use
US20050143297A1 (en) * 2003-05-26 2005-06-30 Jean-Pierre Rosat Method for the administration of ligands, agonists of ligands of the TNF family with reduced toxicity
WO2005053728A2 (de) * 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
WO2006125632A2 (en) * 2005-05-24 2006-11-30 Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy
EP1764109A1 (de) * 2005-05-24 2007-03-21 Xantos Biomedicine AG Agonistische Antikörper, welche an den Tweak Rezeptor Fn14 binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
US20120301444A1 (en) * 2007-09-27 2012-11-29 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof

Also Published As

Publication number Publication date
KR20110117690A (ko) 2011-10-27
US20120020913A1 (en) 2012-01-26
US20140093519A1 (en) 2014-04-03
EP2391385A4 (en) 2013-05-01
BRPI1007529A2 (pt) 2016-10-18
EP2391385A1 (en) 2011-12-07
AU2010208123A2 (en) 2011-08-11
AU2010208123A1 (en) 2011-08-18
JP2012516712A (ja) 2012-07-26
CN102378634A (zh) 2012-03-14
WO2010088534A1 (en) 2010-08-05
CA2751261A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
MX2011007936A (es) Metodos para regeneracion de tejido pancreatico.
MX2023001878A (es) Celulas modificadas geneticamente que comprenden un gen humano modificado de la region constante alfa del receptor de celulas t.
GB0920703D0 (en) Compositions containing satiogens and methods of use
PH12015501470A1 (en) Compositions and methods for the control of nematodes and soil borne diseases
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
MX2018008440A (es) Vectores de terapia genica y citosina deaminasas.
BRPI1013771A2 (pt) "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
WO2007025234A3 (en) Generation of pancreatic endocrine cells from primary duct cell cultures and methods of use for treatment of diabetes
UA115648C2 (uk) Доставка терапевтичних агентів до цнс
BR112013023774A2 (pt) inibidores de glicosilceramida sintase
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
MX354776B (es) Enzimas de reemplazo lisosomal para usarse en el tratamiento de enfermedades de almacenamiento lisosomal.
ZA200805610B (en) Use of mesenchymal stem cells for treating genetic diseases and disorders
MX2010000746A (es) Diferenciacion de celulas madre embrionarias humanas.
MX2010001335A (es) Diferenciacion de celulas madre embrionarias humanas.
HN2011001446A (es) Compuesto utiles para inhibir chk1
MY159971A (en) Multipotent/pluripotent cells and methods
MX2011007647A (es) Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
WO2009137844A3 (en) Pancreatic endocrine progenitor cells derived from pluripotent stem cells
NZ630598A (en) Method of engrafting cells from solid tissues
WO2009089110A3 (en) Methods for repair and regeneration of bone marrow
EP2558124A4 (en) POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION
EP2443231A4 (en) GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM UMBILICAL BLOOD
HK1157814A1 (en) Materials and methods relating to cell based therapies
MX2016005824A (es) Metodo de cultivo celular.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal